Dew -- in your opinion, if and when a decision is made to apply to the EMEA for rights to market the Lovenox generic in the EU, will Sandoz or MNTA make that decision? Would that company also assume the responsibility of meeting EMEA's criteria for approval, e.g., conduct of clinical trial(s)? I guess I'm asking because if the answer is Sandoz, MNTA's plate being rather full may not be too material.
TIA.
John
Market Data 
Markets 
AI
